Considering the potential strategies that may be applied to improve the PI3K/AKT-targeted cancer therapy, development of predictive markers and personalization of each treatment may improve the objective response rate of PI3K/AKT inhibitors and patient survival. The gene discussed is PIK3CA; the disease is cancer.